Literature DB >> 8607668

Adenosine effectively controls pulmonary hypertension after cardiac operations.

D A Fullerton1, S D Jones, F L Grover, R C McIntyre.   

Abstract

BACKGROUND: Pulmonary hypertension secondary to increased pulmonary vascular resistance may greatly complicate the perioperative management of patients having cardiac operations. Adenosine may have a therapeutic role as a selective pulmonary vasodilator. The purpose of this study was to examine the pulmonary hemodynamic effects of a central venous infusion of adenosine in cardiac operative patients with pulmonary hypertension.
METHODS: Ten cardiac patients with pulmonary hypertension (age, 62 +/- 6 years) were studied in the operating room under general anesthesia after weaning from cardiopulmonary bypass. Cardiac output, pulmonary vascular resistance, systemic vascular resistance, mean pulmonary arterial pressure, and mean systemic arterial pressure were determined before, during, and after central venous infusion of adenosine (50 micrograms x kg-1 x min -1) for 15 minutes. Statistical analysis was by analysis of variance, and significance was accepted at p < 0.05.
RESULTS: Adenosine produced significant pulmonary vasodilation. Mean pulmonary arterial pressure was lowered from 36 +/- 1 to 28 +/- 2 mm Hg (p < 0.05), and pulmonary vascular resistance was lowered from 560 +/- 30 to 260 +/- 30 dynes x s x cm-5 (p < 0.05) during adenosine administration. At the same time, cardiac output rose from 4.0 +/- 0.6 to 6.2 L/min (p < 0.05). Pulmonary vascular resistance, mean pulmonary arterial pressure, and cardiac output returned to baseline after the adenosine infusion was stopped. There was no change in systemic mean arterial pressure during adenosine infusion.
CONCLUSIONS: Adenosine may be used clinically as a selective pulmonary vasodilating agent to optimize pulmonary hemodynamic indices without adverse systemic hemodynamic effects in patients with pulmonary hypertension having cardiac operations. It may be particularly valuable in patients with right heart dysfunction by selectively lowering right ventricular afterload.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8607668     DOI: 10.1016/0003-4975(95)01149-8

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  Adenosine myocardial protection: preliminary results of a phase II clinical trial.

Authors:  R M Mentzer; V Birjiniuk; S Khuri; J E Lowe; P S Rahko; R D Weisel; H A Wellons; M L Barker; R D Lasley
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

Review 2.  CD39 in the development and progression of pulmonary arterial hypertension.

Authors:  Abbey Willcox; Natasha Ting Lee; Harshal H Nandurkar; Maithili Sashindranath
Journal:  Purinergic Signal       Date:  2022-08-10       Impact factor: 3.950

3.  Coronary Bypass Surgery in Patients with Pulmonary Hypertension: Assessment of Early and Long Term Results.

Authors:  Baris Akca; Nevzat Erdil; Olcay Murat Disli; Koksal Donmez; Feray Erdil; Mehmet Cengiz Colak; Bektas Battaloglu
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-03-09       Impact factor: 1.520

Review 4.  Recognition and management of pulmonary hypertension.

Authors:  J C Wanstall; T K Jeffery
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

5.  Adenosine Inhibits Ovarian Cancer Growth Through Regulating RhoGDI2 Protein Expression.

Authors:  Bing Xia; Jing Wang
Journal:  Drug Des Devel Ther       Date:  2019-11-08       Impact factor: 4.162

Review 6.  Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.

Authors:  Laura C Price; Stephen J Wort; Simon J Finney; Philip S Marino; Stephen J Brett
Journal:  Crit Care       Date:  2010-09-21       Impact factor: 9.097

7.  Serum-Free Thyroxine Levels Were Associated with Pulmonary Hypertension and Pulmonary Artery Systolic Pressure in Euthyroid Patients with Coronary Artery Disease.

Authors:  Bingjie Wu; Jingjing Jiang; Minghui Gui; Lin Liu; Qiqige Aleteng; Shanshan Wang; Xiaojing Liu; Yan Ling; Xin Gao
Journal:  Int J Endocrinol       Date:  2017-06-22       Impact factor: 3.257

8.  Purinergic Dysfunction in Pulmonary Arterial Hypertension.

Authors:  Zongye Cai; Ly Tu; Christophe Guignabert; Daphne Merkus; Zhichao Zhou
Journal:  J Am Heart Assoc       Date:  2020-09-01       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.